See What’s Possible in Packaging & Processing @ PACK EXPO International
See packaging & processing solutions from 2,600 exhibitors and gain insights from 150+ free educational sessions at PACK EXPO International.
REGISTER NOW & SAVE

Create a free Packaging World account to continue reading

Wake Up to Urinate Too Often? Allergan’s Got Your Back.

FDA approves the first treatment to combat nighttime trips to the bathroom: a nasal spray that decreases urine production.

Noctiva / Image: Business Wire
Noctiva / Image: Business Wire

There’s nothing worse than leaving the warmth and security of your bed in the middle of the night to venture to the bathroom. A recent article from Endpoints News has the answer to our prayers: a nasal spray that inhibits urine production at night. The drug is called Noctiva; it was developed by Allergan and then signed over to Serenity Pharmaceuticals in a commercialization deal.

The drug works by increasing urine absorption in the kidneys with a dose taken 30 minutes before bedtime to limit the effect to just nighttime. The drug will soon hit shelves with a black box label warning that notes the risk of dangerously low sodium levels. The drug passed an FDA vote 14-4, but some experts expressed concern that the drug could be dangerous for elderly patients with congestive heart failure or hypertension.

Discover How to Stay Ahead of the Competition at PACK EXPO International
See new solutions from 2,600 exhibitors. Gain insights from 150+ free educational sessions. From automation & robotics to real-time data insights, find the tech for your company’s future at North America’s largest packaging & processing event.
REGISTER NOW & SAVE
Discover How to Stay Ahead of the Competition at PACK EXPO International
Co-packers: the competitive gap is widening
Brands want more than low bids. See what automation, services, and sustainability mean for CM/CPs in 2026.
Read More
Co-packers: the competitive gap is widening